Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

April 30, 2012

Study Completion Date

December 31, 2012

Conditions
Head and Neck Cancer
Interventions
BIOLOGICAL

bevacizumab

Bevacizumab IV over 30-90 minutes once every 2 weeks for up to 1 year. Bevacizumab, which stops 8 weeks before surgery, may restart 4 weeks after surgery and continue for 9 months in the absence of disease progression or unacceptable toxicity.

DRUG

docetaxel

docetaxel IV over 1 hour once a week for 8 weeks

PROCEDURE

conventional surgery

8-10 weeks after the completion of chemoradiotherapy, patients may undergo neck dissection

RADIATION

radiation therapy

radiotherapy once daily, 5 days a week, for 8 weeks

Trial Locations (6)

15232

UPMC Cancer Centers, Pittsburgh

44060

Lake/University Ireland Cancer Center, Mentor

44122

UHHS Chagrin Highlands Medical Center, Orange Villager

44130

Southwest General Health Center, Middleburg Heights

44145

UHHS Westlake Medical Center, Westlaker

44106-5065

Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00281840 - Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer | Biotech Hunter | Biotech Hunter